Yesterday IB went limit up ,,premature ejaculation...quickly pulled out....n collect cheap...today the real real Fffed limit up...wakakaka....kokokokokokkkk
Recommend pecca for those who is late here. Have been having good lead on PPE, buying more machines to increase production, applying FDA, main business partners (perodua) all time high sales, havent include other clients, have been making profit all these time.
DNONCE TECHNOLOGY Key Highlights • Significant improvement in Profit Before Tax (“PBT”) from loss of RM3.34 million in 1H Year-to-date (“YTD”) 30 June 2019 to RM2.40 million, an increase of RM5.74 million or 172% for Financial Year Ended 30 April 2020 (“FYE 30 April 2020”). • Noteworthy surge in revenue, average monthly sales for July 2019 till April 2020 was RM14.6 million compared with January 2019 till June 2019 of RM13.3 million representing a 9.8% increase, even though March and April sales were impacted by the Covid-19 induced MCO • Three consecutive profitable quarters with FYE PBT of RM2.40 million signifying 9 straight months of profit until April since the new management took over the running of the Company. D’nonce Technology Bhd (“D’nonce” or “the Group”) (“7114”), today announced its interim financial results for the sixth quarter (“Q6”) and 16-month consolidated financial results for its Financial Year Ended 30 April 2020 (“FYE 30 April 2020”). DNONCE is a diversified engineering solutions provider, serving customers in the semiconductor, automotive, medical/healthcare, data storage hardware and consumer electronics industries with overseas subsidiaries in Thailand. In mid-July 2019, D’nonce had installed a new Board of Directors and management, led by Mr. Tho Yow Yin as CEO. Under the new leadership. DNONCE embarked on costcutting measures and redirected their focus to expand the Group’s growth in value-added businesses. These efforts have borne positive results as reflected in its financial performance since July 2019 to 30 April 2020. D’nonce recorded a revenue of RM225 million for the FYE 30 April 2020, of which from 1 July 2019 to 30 April 2020, the Group recorded an average monthly revenue of RM14.6 million as compared to an average monthly revenue of RM13.3 million from 1 January 2019 to 30 June 2019, representing a 9.8% improvement in sales, despite the MCO which impacted operations in March and April 2020. The significant increment of the revenue was partly contributed by the surge in demand from customers in the healthcare industry mainly due to the Covid-19 outbreak as D’nonce provides essential support to the glove industry in Southern Thailand and also supplies injection molded ventilator parts from their factory in Prai, Pulau Pinang. Simultaneously, DNONCE continued to showcase a healthy and growing PBT having recorded a PBT of RM2.40 million for the Financial Period Ended 30 April 2020 reflecting a turnaround of RM5.74 million or 172% growth over the 1H Loss Before Tax of RM3.34 million. With the exception of Q6 FY2020 (which consisted of only 1 month), the Group achieved three consecutive quarters in the black (cumulative PBT of RM5.74 million from 1 July 2019 to 30 April 2020) - after losses earlier in the financial year throughout the first two quarters (cumulative Loss Before Tax of RM3.34 million from 1 January 2019 to 30 June 2019).
This is the result of the DNONCE Management’s continuous prudence in managing its expenses while expanding revenue, resulting in the highest level of operational efficiency and also the continuous growth of its business. As of 30th April 2020 the Group has generated a positive cash flow of RM8.16 million from operating activities and have cash and bank balances of RM32.5 million. For the full FYE 30 April 2020, D’nonce recorded a Profit After Tax of RM0.73 million (after the non-cash adjustment from the revaluation of properties deficit of RM0.45 million) in spite of the net losses recorded for Financial Period Ended 30 June 2019. Notwithstanding the challenging environment, DNONCE is cautiously optimistic of its business with the expectation of continued strong demand for its supplies to the medical and health sectors as well as the positive demand from the electronic technology sector moving forward. DNONCE has active initiatives underway to enhance its overall organisational effectiveness. These initiatives should increase productivity and cost efficiency while also helping to realise scale economies as Dnonce continues to grow its commercial opportunities.
两大利好围绕DNONCE!! 1)Provides Essential Support (Glove Industry) Southern Thailand
2) Injection Molded Ventilator Parts (Prai, Pulau Pinang)
Q3 2020 just announced today. Company has turned around in Q3 2020 with EPS of 6.04 sen. The share price is closed at 64 sen today. If net profit can be achieved consistently for the next 4 quarters, EPS will be 24 sen. The share price will be undervalued at PE 10.
Tasco also announced very good performance yesterday. Its Q2 2020 EPS is 5.35 sen. Share price has gone up to RM2.30 as at Friday. EPS 5.35 sen x 4 = 21.4 sen. It is traded at PE of 11 times.
Guys, don't you see the red flag here? pass few months the founder himself and the company have been selling their own stocks, its not the time to buy again, wait under 0.5c to consider. There's no big moves from texchem, its all the same sushi and chemicals, and so it'll produce the same p/l as it always have.
Sinopharm Vaccine (linked to Kanger) is on track for full approval in November or December
“The most promising of these, developed by Wuhan-based Sinopharm, is already being given to frontline workers in the United Arab Emirates. According to Wu Guizhen, chief biosafety expert at the Chinese Center for Disease Control and Prevention, Sinopharm’s candidate is on track for full approval this month or next.”
Vaccination started in UK. Anticipated the demand for Face-Shield will be diminishing in next six months, entailing the share price starts to drops, whereas the restaurant business that made RM20 mil loss one time this year would improve. Texchem's dilemma
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
thomc
66 posts
Posted by thomc > 2020-08-10 09:49 | Report Abuse
Early stage of limit up... Huat ah....